Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Cspc Megalith Biopharmaceutical Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, PUTTLITZ, KARL J, who is the busiest examiner with 1 pending office action. The prosecution is occurring within 1 distinct art unit. This profile shows a very focused and singular prosecution effort.
With 1 pending office action, the company's immediate patent goals are tied to the 1 distinct examiner. Practitioners should prepare for a targeted interaction with PUTTLITZ, KARL J. The presence of only 1 distinct art unit suggests a specialized technology. This simple structure allows the practitioner to focus all efforts on the specific requirements of the 1 pending office action without managing multiple examiners. Because PUTTLITZ, KARL J is the busiest examiner with 1 pending office action, the outcome of the 1 distinct art unit review is the primary factor for the company's current portfolio success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711374 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711374 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCspc Megalith Biopharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karl J Puttlitz has the most, with 1 of Cspc Megalith Biopharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
